申请人:Glaxo Group Limited
公开号:US05475020A1
公开(公告)日:1995-12-12
The invention relates to indoles of general formula (I) ##STR1## wherein R.sub.0 represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sub.1 represents a group R.sub.4 CONH--, R.sub.4 R.sub.5 NSO.sub.2 --, R.sub.4 SO.sub.2 NH-- or R.sub.4 R.sub.5 NCO-- (where R.sub.4 is a hydrogen atom or a C.sub.1-6 alkyl group, provided that R.sub.4 does not represent a hydrogen atom when R.sub.1 represents R.sub.4 SO.sub.2 NH--, and R.sub.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, phenyl or phen(C.sub.1-3)alkyl group in which the phenyl ring is optionally substituted by a halogen atom or a C.sub.1-4 alkoxy, hydroxy or C.sub.1-3 alkyl group); R.sub.2 is a hydrogen atom, a C.sub.1-3 alkyl, a C.sub.3-6 alkenyl, a phenyl or a phen(C.sub.1-3)alkyl group; R.sub.3 is a hydrogen atom, a C.sub.1-3 alkyl group or a group --CO.sub.2 R.sub.6, --COR.sub.6, --COCO.sub.2 R.sub.6 or --CONHR.sub. 6 where R.sub.6 is a hydrogen atom or a C.sub.1-4 alkyl, a C.sub.3-7 cycloalkyl, a C.sub.3-6 alkenyl, an aryl or an ar(C.sub.1-4)alkyl group in which the aryl group may be unsubstituted or substituted by a halogen atom or a C.sub.1-4 alkoxy, C.sub.1-4 alkyl or hydroxy group, provided that when R.sub.3 is --CO.sub.2 R.sub.6, R.sub.6 is other than hydrogen; n is zero or an integer from 1 to 5; and pharmaceutically acceptable salts thereof.
该发明涉及通式(I)的吲哚化合物
其中R0代表氢原子或C1-3烷基基团;R1代表基团R4CONH-、R4R5NSO2-、R4SO2NH-或R4R5NCO-(其中R4为氢原子或C1-6烷基基团,但当R1代表R4SO2NH-时,R4不代表氢原子,而R5为氢原子或C1-6烷基、C3-7环烷基、苯基或苄基,其中苯环可以选择性地被卤原子或C1-4烷氧基、羟基或C1-3烷基基团取代);R2为氢原子、C1-3烷基、C3-6烯基、苯基或苄基;R3为氢原子、C1-3烷基或基团--CO2R6、--COR6、--COCO2R6或--CONHR6,其中R6为氢原子或C1-4烷基、C3-7环烷基、C3-6烯基、芳基或芳基(C1-4)烷基基团,其中芳基基团可以是未取代或被卤原子或C1-4烷氧基、C1-4烷基或羟基基团取代,但当R3为--CO2R6时,R6不是氢原子;n为零或1到5之间的整数;及其药学上可接受的盐。